Cytoskeletal active rho kinase inhibitor compounds, composition and use
View Patent ↗The present invention is directed to synthetic cytoskeletal active compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with cytoskeletal reorganization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or Formula II, wherein said amount is effective to influence the actomyosin interactions, for example by leading to cellular relaxation and alterations in cell-substratum adhesions.
1. A compound of Formula II:
wherein:
Q is (CR 4 R 5 ) n3;
n 1 is 1;
n 2 is 1;
n 3 is 1-3;
R 2 is isoquinoline-5-yl:
Ar is a monocyclic aryl or bicyclic aryl;
X is from 1 to 3 substituents on Ar, and each is independently selected from the group consisting of OR 8 , NR 8 R 9 , SR 8 , SOR 8 , SO 2 R 8 , SO 2 NR 8 R 9 , NR 8 SO 2 R 9 , CONR 8 R 9 , NR 8 C(═O)R 9 , NR 8 C(═O)OR 9 , OC(═O)NR 8 R 9 , and NR 8 C(═O)NR 9 R 10 ;
R 3 is H;
R 4 is H;
R 5 is H or alkyl;
R 8 is H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, (heterocycle)alkyl, (heterocycle)alkenyl, (heterocycle)alkynyl, or heterocycle; optionally substituted by one or more halogen or heteroatom-containing substituents selected from the group consisting of OR 11 , NR 11 R 12 , NO 2 , SR 11 , SOR 11 , SO 2 R 11 , SO 2 NR 11 R 12 , NR 11 SO 2 R 12 , OCF 3 , CONR 11 R 12 , NR 11 C(═O)R 12 , NR 11 C(═O)OR 12 , OC(═O)NR 11 R 12 , and NR 11 C(═O)NR 12 R 13 ;
R 9 and R 10 are independently H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, (heterocycle)alkyl, (heterocycle)alkenyl, (heterocycle)alkynyl, or heterocycle; optionally substituted by one or more halogen or heteroatom-containing substituents selected from the group consisting of OR 14 , NR 14 R 15 , NO 2 , SR 14 , SOR 14 , SO 2 R 14 , SO 2 NR 14 R 15 , NR 14 SO 2 R 15 , OCF 3 , CONR 14 R 15 , NR 14 C(═O)R 15 , NR 14 C(═O)OR 15 , OC(═O)NR 14 R 15 , and NR 14 C(═O)NR 15 R 16 ;
R 11 -R 17 are independently H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, (heterocycle)alkyl, (heterocycle)alkenyl, (heterocycle)alkynyl, or heterocycle;
with the proviso that if X is acyclic and is connected to Ar by an oxygen or nitrogen atom, then X contains at least one additional oxygen, nitrogen or sulfur atom.
2. The compound according to claim 1 , wherein Q is CH 2 , and R 3 is H.
3. The compound according to claim 1 , wherein R 4 and R 5 are H.
4. The compound according to claim 1 , wherein R 8 is H, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, or heterocycle.
5. A compound selected from the group consisting of: Compound 2.039,
which is (R)-2-(3-((3-(isoquinolin-5-ylamino)pyrrolidin-1-yl)methyl)phenoxy)ethanol; Compound 2.008, which is N-(4-((3-(isoquinolin-5-ylamino)pyrrolidin-1-yl)methyl)phenyl)acetamide; Compound 2.032, which is (S)-2-(3-((3-(isoquinolin-5-ylamino)pyrrolidin-1-yl)methyl)phenoxy)ethanol; Compound 2.035, which is (S)—N-(3-((3-(isoquinolin-5-ylamino)pyrrolidin-1-yl)methyl)phenyl)methanesulfonamide; Compound 2.040, which is (R)-2-(3-((3-(isoquinolin-5-ylamino)pyrrolidin-1-yl)methyl)phenoxy)acetamide; Compound 2.041, which is (R)—N-(3-((3-(isoquinolin-5-ylamino)pyrrolidin-1-yl)methyl)phenyl)ethanesulfonamide; Compound 2.042, which is 2-(3-((3-(isoquinolin-5-ylamino)pyrrolidin-1-yl)methyl)phenoxy)ethanol; Compound 2.043, which is (R)-2-(3-((3-(isoquinolin-5-ylamino)pyrrolidin-1-yl)methyl)phenoxy)-1-morpholinoethanone; Compound 2.044, which is (R)-2-(3-((3-(isoquinolin-5-ylamino)pyrrolidin-1-yl)methyl)phenoxy)acetic acid; Compound 2.021, which is (R)—N-(1-(4-(cyclopropylthio)benzyl)pyrrolidin-3-yl)isoquinolin-5-amine; Compound 2.024, which is (S)—N-(1-(4-(cyclopropylthio)benzyl)pyrrolidin-3-yl)isoquinolin-5-amine; Compound 2.026, which is (R)—N-(1-(4-(methylthio)benzyl)pyrrolidin-3-yl)isoquinolin-5-amine; and Compound 2.029, which is (S)—N-(1-(4-(methylthio)benzyl)pyrrolidin-3-yl)isoquinolin-5-amine.
6. A method for reducing intraocular pressure in a subject in need thereof, comprising the steps of:
identifying a subject in need thereof, and
administering to the subject the compound according to claim 1 , in an amount effective to inhibit actomyosin interactions.
7. The method according to claim 6 , wherein said method treats glaucoma.
8. A compound of Formula II:
wherein:
Q is (CR 4 R 5 ) n3 ;
n 1 is 1;
n 2 is 1;
n 3 is 1-3;
R 2 is isoquinoline-5-yl:
Ar is a monocyclic aryl or bicyclic aryl;
X is from 1 to 3 substituents on Ar, each independently in the form Y-Z, in which Z is attached to Ar;
Y is one or more substituents on Z, and each is independently selected from the group consisting of H, halogen, OR 8 , NR 8 R 9 , NO 2 , SR 8 , SOR 8 , SO 2 R 8 , SO 2 NR 8 R 9 , NR 8 SO 2 R 9 , OCF 3 , CONR 8 R 9 , NR 8 C(═O)R 9 , NR 8 C(═O)OR 9 , OC(═O)NR 8 R 9 , and NR 8 C(═O)NR 9 R 10 ;
Z is alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heterocycle, (heterocycle)alkyl, (heterocycle)alkenyl, and (heterocycle)alkynyl;
R 3 is H;
R 4 is H;
R 5 is H or alkyl;
R 8 is H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, (heterocycle)alkyl, (heterocycle)alkenyl, (heterocycle)alkynyl, or heterocycle; optionally substituted by one or more halogen or heteroatom-containing substituents selected from the group consisting of OR 11 , NR 11 R 12 , NO 2 , SR 11 , SOR 11 , SO 2 R 11 , SO 2 NR 11 R 12 , NR 11 SO 2 R 12 , OCF 3 , CONR 11 R 12 , NR 11 C(═O)R 12 , NR 11 C(═O)OR 12 , OC(═O)NR 11 R 12 , and NR 11 C(═O)NR 12 R 13 ;
R 9 and R 10 are independently H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, (heterocycle)alkyl, (heterocycle)alkenyl, (heterocycle)alkynyl, or heterocycle; optionally substituted by one or more halogen or heteroatom-containing substituents selected from the group consisting of OR 14 , NR 14 R 15 , NO 2 , SR 14 , SOR 14 , SO 2 R 14 , SO 2 NR 14 R 15 , NR 14 SO 2 R 15 , OCF 3 , CONR 14 R 15 , NR 14 C(═O)R 15 , NR 14 C(═O)OR 15 , OC(═O)NR 14 R 15 , and NR 14 C(═O)NR 15 R 16 ;
wherein any two of the groups R 8 , R 9 and R 10 are optionally joined with a link selected from the group consisting of bond, —O—, —S—, —SO—, —SO 2 —, and —NR 17 — to form a ring; and
R 11 -R 17 are independently H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, (heterocycle)alkyl, (heterocycle)alkenyl, (heterocycle)alkynyl, or heterocycle.
9. The compound according to claim 8 , wherein said compound is selected from the group consisting of: Compound 2.019, which is (S)—N-(1-(4-cyclopropylbenzyl)pyrrolidin-3-yl)isoquinolin-5-amine; Compound 2.020, which is (R)—N-(1-(3-cyclopropylbenzyl)pyrrolidin-3-yl)isoquinolin-5-amine; Compound 2.022, which is (R)—N-(1-(4-cyclopropylbenzyl)pyrrolidin-3-yl)isoquinolin-5-amine; Compound 2.023, which is (S)—N-(1-(3-cyclopropylbenzyl)pyrrolidin-3-yl)isoquinolin-5-amine; and Compound 2.031, which is (R)—N-(1-(4-ethynylbenzyl)pyrrolidin-3-yl)isoquinolin-5-amine.
10. A method of reducing intraocular pressure in a subject in need thereof, comprising the steps of:
identifying a subject in need thereof, and
administering to the subject the compound according to claim 8 , in an amount effective to inhibit actomyosin interactions.
11. A compound of Formula II:
wherein:
Q is (CR 4 R 5 ) n3 ;
n 1 is 1;
n 2 is 1;
n 3 is 1-3;
R 2 is isoquinoline-5-yl:
Ar is a monocyclic aryl or bicyclic aryl;
X is from 1 to 3 substituents on Ar, each independently in the form Y-Z, in which Z is attached to Ar;
Y is one or more substituents on Z, and each is independently OR 8 , NR 8 R 9 , NO 2 , SR 8 , SOR 8 , SO 2 R 8 , SO 2 NR 8 R 9 , NR 8 SO 2 R 9 , OCF 3 , CONR 8 R 9 , NR 8 C(═O)R 9 , NR 8 C(═O)OR 9 , OC(═O)NR 8 R 9 , or NR 8 C(═O)NR 9 R 10 ;
Z is alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heterocycle, (heterocycle)alkyl, (heterocycle)alkenyl, or (heterocycle)alkynyl;
R 3 is H;
R 4 is H;
R 5 is H or alkyl;
R 8 is H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, (heterocycle)alkyl, (heterocycle)alkenyl, (heterocycle)alkynyl, or heterocycle; optionally substituted by one or more halogen or heteroatom-containing substituents selected from the group consisting of OR 11 , NR 11 R 12 , NO 2 , SR 11 , SOR 11 , SO 2 R 11 , SO 2 NR 11 R 12 , NR 11 SO 2 R 12 , OCF 3 , CONR 11 R 12 , NR 11 C(═O)R 12 , NR 11 C(═O)OR 12 , OC(═O)NR 11 R 12 , and NR 11 C(═O)NR 12 R 13 ;
R 9 and R 10 are independently H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, (heterocycle)alkyl, (heterocycle)alkenyl, (heterocycle)alkynyl, or heterocycle; optionally substituted by one or more halogen or heteroatom-containing substituents selected from the group consisting of OR 14 , NR 14 R 15 , NO 2 , SR 14 , SOR 14 , SO 2 R 14 , SO 2 NR 14 R 15 , NR 14 SO 2 R 15 , OCF 3 , CONR 14 R 15 , NR 14 C(═O)R 15 , NR 14 C(═O)OR 15 , OC(═O)NR 14 R 15 , or NR 14 C(═O)NR 15 R 16 ;
wherein any two of the groups R 8 , R 9 and R 10 are optionally joined with a link selected from the group consisting of bond, —O—, —S—, —SO—, —SO 2 —, and —NR 17 — to form a ring; and
R 11 -R 17 are independently H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, (heterocycle)alkyl, (heterocycle)alkenyl, (heterocycle)alkynyl, or heterocycle;
with the proviso that when Z is selected from the group consisting of alkyl, alkenyl, and alkynyl, and Y falls on the carbon by which Z is attached to Ar, then Y contains at least one nitrogen or sulfur atom.
12. A method of reducing intraocular pressure in a subject in need thereof, comprising the steps of:
identifying a subject in need thereof, and
administering to the subject the compound according to claim 11 , in an amount effective to inhibit actomyosin interactions.
13. The compound of claim 1 , wherein Ar is phenyl.
14. The compound of claim 13 , wherein X is from 1 to 3 substituents on Ar, and X is OR 8 or NR 8 SO 2 R 9 .
15. The compound of claim 14 , wherein R 8 is H, alkyl, arylalkyl, cycloalkylalkyl, optionally substituted with OR 11 , NR 11 SO 2 R 12 , or CONR 11 R 12 .
16. The compound of claim 8 , wherein Ar is phenyl.
17. The compound of claim 16 , wherein X is from 1 to 3 substituents on Ar, each independently in the form Y-Z, Z is absent, and one of Y is halogen, OR 8 , or NR 8 SO 2 R 9 .
18. The compound of claim 17 , wherein R 8 is H, alkyl, arylalkyl, cycloalkylalkyl, optionally substituted with OR 11 , NR 11 SO 2 R 12 , or CONR 11 R 12 .
19. The compound of claim 1 , wherein the compound has a R configuration on a central pyrrolidine ring.